Genetic Testing and Life Insurance in 2026: NIH Study Proposes New Ethical Framework for Underwriting
A groundbreaking study from the National Institutes of Health (NIH) published in June 2026 is challenging the life insurance industry’s long-standing approach to genetic information — and proposing a middle-ground framework that could reshape how carriers evaluate applicants in the coming years.
The research, published in the Journal of Law and the Biosciences (2026;13(1)), tackles one of the most contentious debates in insurance underwriting: whether life insurers should be allowed to consider an applicant’s genetic test results when setting premiums or denying coverage. The study’s authors — led by Benjamin E. Berkman of the NIH Department of Bioethics, along with Harisan Nasir, Leila Jamal, Chloe Connor, and Anya E.R. Prince — argue that the current “actuarial fairness” standard gives insurers too much latitude, and propose a more nuanced “actuarial utility” framework instead.
The Current Legal Landscape: GINA and the Life Insurance Loophole
Most Americans assume their genetic information is protected. The Genetic Information Nondiscrimination Act (GINA) of 2008 made it illegal for health insurers and employers to discriminate based on genetic test results. But GINA contains a critical carve-out: it does not apply to life insurance, disability insurance, or long-term care insurance.
This means that if you’ve taken a 23andMe test, undergone BRCA screening for breast cancer risk, or participated in any genetic research study, a life insurance company can legally request those results during underwriting — and use them to raise your premiums or deny coverage entirely. The only protection consumers have is a patchwork of state laws, with some states offering additional restrictions while others provide none at all.
| Protection Area | Health Insurance | Employment | Life Insurance | Disability Insurance | Long-Term Care Insurance |
|---|---|---|---|---|---|
| GINA (Federal, 2008) | ✓ Protected | ✓ Protected | ✗ NOT Protected | ✗ NOT Protected | ✗ NOT Protected |
| Florida HB 1189 (2020) | ✓ Protected | ✓ Protected | ✓ Consent Required | ✓ Consent Required | ✓ Consent Required |
| California State Law | ✓ Protected | ✓ Protected | Partial Restrictions | Partial Restrictions | Partial Restrictions |
| Most Other States | ✓ Protected | ✓ Protected | ✗ No Protection | ✗ No Protection | ✗ No Protection |
What the NIH Study Proposes: Actuarial Fairness vs. Actuarial Utility
The NIH researchers identify two competing frameworks that dominate the genetic-information debate:
- Actuarial Fairness: The traditional insurance principle that individuals should pay premiums proportional to the risk they bring to the insurance pool. Under this standard, insurers argue they need full access to genetic data to price policies accurately. Current U.S. law and policy largely defer to this approach, giving carriers wide latitude to use genetic information.
- Actuarial Utility: A middle-ground framework the NIH team proposes. Rather than granting blanket access or imposing a total ban, this approach asks a more precise question: does a specific piece of genetic information actually improve risk prediction in a meaningful way? Not all genetic markers are equally predictive, and the study argues that policy should distinguish between genetic data that genuinely enhances underwriting accuracy and data that doesn’t.
| Dimension | Actuarial Fairness (Current Standard) | Actuarial Utility (NIH Proposal) |
|---|---|---|
| Core Principle | Pay for the risk you bring to the pool | Only use genetic data that meaningfully improves risk prediction |
| Insurer Access to Genetic Data | Broad — all genetic information is fair game | Targeted — must demonstrate predictive value per marker |
| Consumer Impact | Genetic test results can raise premiums or trigger denial | Only proven predictive markers affect underwriting |
| Polygenic Risk Scores | Insurers can use them without restriction | Must pass actuarial utility threshold first |
| Regulatory Approach | Deferential to insurers | Evidence-based, marker-by-marker review |
“Both sides employ concepts of fairness and discrimination in supporting their position,” the researchers note. “This article takes seriously a middle-ground approach, broadly labeled as actuarial utility.” The framework would require insurers to demonstrate that specific genetic information has proven predictive value before using it in underwriting decisions — a standard that emerging genetic technologies like polygenic risk scores would need to meet.
Why This Matters to Consumers Considering Genetic Testing
For the millions of Americans who have already taken direct-to-consumer genetic tests or are considering clinical genetic screening, the NIH study raises practical questions about the timing of testing relative to insurance applications.
Currently, if you apply for life insurance before undergoing genetic testing, the insurer has no test results to review — and cannot penalize you for information that doesn’t exist yet. But if you’ve already been tested and the results are in your medical records, those results are fair game during underwriting. This creates a perverse incentive: consumers who want both genetic insights and affordable life insurance are effectively told to buy coverage first and test later.
The NIH framework, if adopted, would change this dynamic by requiring insurers to justify which genetic results they use and why — rather than treating all genetic information as automatically relevant. A BRCA mutation with well-established cancer risk correlations might meet the actuarial utility standard, while a polygenic risk score for a condition with weak predictive power might not.
The Insurance Industry’s Position
Life insurers have consistently argued for access to genetic information on actuarial fairness grounds. Their position is straightforward: if an applicant knows they carry a genetic mutation that significantly increases mortality risk, and the insurer does not, the risk pool becomes unbalanced. Healthy applicants subsidize higher-risk ones, and premiums rise for everyone.
Industry trade groups have also pointed out that life insurance is voluntary — unlike health insurance, which GINA protects because everyone needs medical care. The argument is that genetic information is no different from other health data insurers already use, such as family history, blood pressure, and cholesterol levels.
However, consumer advocates counter that genetic information is fundamentally different: it’s immutable, it can reveal risks for conditions that may never develop, and it affects family members who share the same genetic profile. A genetic test result doesn’t just affect the individual tested — it can impact siblings, children, and parents who never consented to the test.
What Could Change in 2026 and Beyond
The NIH study arrives at a moment when genetic testing is becoming cheaper, more widespread, and more predictive. Polygenic risk scores — which combine hundreds or thousands of genetic variants to estimate disease risk — are moving from research labs into clinical practice. Whole-genome sequencing, once costing thousands of dollars, is approaching the $200 mark.
Several states are already considering legislation to close the GINA life insurance loophole. Florida’s genetic privacy law (HB 1189, passed in 2020) prohibits life insurers from using genetic information without consent, and similar bills have been introduced in other states. At the federal level, the NAIC (National Association of Insurance Commissioners) has periodically revisited the issue but has not adopted a model regulation.
The NIH framework offers policymakers a practical path forward: rather than choosing between total insurer access and a complete ban, regulators could require insurers to demonstrate actuarial utility for each genetic marker they wish to use. This would allow genuinely predictive genetic information to inform underwriting while protecting consumers from discrimination based on weak or unproven genetic associations.
Practical Steps for Consumers in 2026
While the policy debate unfolds, consumers have several practical options to protect their insurability:
- Apply for life insurance before genetic testing: If you’re planning both, sequence matters. Lock in coverage based on your current known health status, then pursue genetic insights afterward. Once a policy is in force, insurers generally cannot cancel it or raise premiums based on new genetic information discovered later.
- Choose no-medical-exam policies: Simplified issue and guaranteed issue life insurance policies skip the full medical underwriting process, including access to genetic test results. While these policies typically have lower coverage limits and higher premiums, they provide a path to coverage for consumers concerned about genetic privacy. See our no medical exam life insurance guide for carrier comparisons.
- Compare carriers carefully: Different insurers have different underwriting guidelines for genetic conditions. Some carriers are more lenient than others for applicants with known genetic markers. Working with an independent broker who can shop across 60+ carriers — rather than a captive agent tied to one company — gives you the best chance of finding favorable underwriting. Our best life insurance companies guide ranks carriers by underwriting flexibility.
- Understand your state’s protections: If you live in Florida, California, or another state with genetic privacy laws beyond GINA, you have additional safeguards. Check your state insurance department’s website or consult our life insurance buying checklist for state-specific guidance.
Related Resources
- National Human Genome Research Institute: Genetic Discrimination — Federal GINA overview and limitations
- NAIC Consumer Resources — State insurance regulator contact information
- AM Best Insurance Ratings — Check your insurer’s financial strength before applying
Frequently Asked Questions
Key Takeaway: The NIH’s actuarial utility framework offers a practical path between total insurer access to genetic data and a complete ban. For consumers, the safest strategy remains unchanged: secure life insurance coverage before undergoing genetic testing whenever possible. If you’re concerned about how your genetic information might affect your insurability, our licensed agents can help you compare policies from top-rated carriers and find coverage that fits your needs.
Compare life insurance quotes from 60+ top-rated carriers →
Sources: NIH/Journal of Law and the Biosciences (DOI: 10.1093/jlb/lsag017, June 2026); Genetic Information Nondiscrimination Act of 2008 (Pub.L. 110-233); Florida HB 1189 (2020); NAIC Consumer Resources.
